Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial
Purpose: Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non–small-cell lung cancer (NSCLC), based on the importance of the signaling pathways involved in tumor growth, angiogenesis, and metastasis. This phase III trial investigated overall survival (OS) f...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
May 7, 2012
|
| In: |
Journal of clinical oncology
Year: 2012, Jahrgang: 30, Heft: 17, Pages: 2070-2078 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2011.39.2993 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1200/JCO.2011.39.2993 Verlag, kostenfrei, Volltext: http://ascopubs.org/doi/abs/10.1200/JCO.2011.39.2993?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed& 
|
| Verfasserangaben: | Giorgio V. Scagliotti, Maciej Krzakowski, Aleksandra Szczesna, Janos Strausz, Anatoly Makhson, Martin Reck, Rafal F. Wierzbicki, Istvan Albert, Michael Thomas, Jose Elias Abrao Miziara, Zsolt S. Papai, Nina Karaseva, Sumitra Thongprasert, Elsa Dalmau Portulas, Joachim von Pawel, Ke Zhang, Paulina Selaru, Lesley Tye, Richard C. Chao, and Ramaswamy Govindan |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1581152930 | ||
| 003 | DE-627 | ||
| 005 | 20220815014229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180920s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2011.39.2993 |2 doi | |
| 035 | |a (DE-627)1581152930 | ||
| 035 | |a (DE-576)511152930 | ||
| 035 | |a (DE-599)BSZ511152930 | ||
| 035 | |a (OCoLC)1341019041 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Scagliotti, Giorgio V. |e VerfasserIn |0 (DE-588)1077326319 |0 (DE-627)83633342X |0 (DE-576)446219193 |4 aut | |
| 245 | 1 | 0 | |a Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer |b a phase III trial |c Giorgio V. Scagliotti, Maciej Krzakowski, Aleksandra Szczesna, Janos Strausz, Anatoly Makhson, Martin Reck, Rafal F. Wierzbicki, Istvan Albert, Michael Thomas, Jose Elias Abrao Miziara, Zsolt S. Papai, Nina Karaseva, Sumitra Thongprasert, Elsa Dalmau Portulas, Joachim von Pawel, Ke Zhang, Paulina Selaru, Lesley Tye, Richard C. Chao, and Ramaswamy Govindan |
| 264 | 1 | |c May 7, 2012 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online ahead of print on May 7, 2012 | ||
| 500 | |a Gesehen am 20.09.2018 | ||
| 520 | |a Purpose: Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non–small-cell lung cancer (NSCLC), based on the importance of the signaling pathways involved in tumor growth, angiogenesis, and metastasis. This phase III trial investigated overall survival (OS) for sunitinib plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC. Patients and Methods: Patients previously treated with one to two chemotherapy regimens (including one platinumbased regimen) for recurrent NSCLC, and for whom erlotinib was indicated, were randomly assigned (1:1) to sunitinib 37.5 mg/d plus erlotinib 150 mg/d or to placebo plus erlotinib 150 mg/d, stratified by prior bevacizumab use, smoking history, and epidermal growth factor receptor expression. The primary end point was OS. Key secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety. | ||
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 30(2012), 17, Seite 2070-2078 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer a phase III trial |
| 773 | 1 | 8 | |g volume:30 |g year:2012 |g number:17 |g pages:2070-2078 |g extent:9 |a Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer a phase III trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2011.39.2993 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://ascopubs.org/doi/abs/10.1200/JCO.2011.39.2993?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed& |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180920 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 9 | ||
| 999 | |a KXP-PPN1581152930 |e 3025917865 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Giorgio V. Scagliotti, Maciej Krzakowski, Aleksandra Szczesna, Janos Strausz, Anatoly Makhson, Martin Reck, Rafal F. Wierzbicki, Istvan Albert, Michael Thomas, Jose Elias Abrao Miziara, Zsolt S. Papai, Nina Karaseva, Sumitra Thongprasert, Elsa Dalmau Portulas, Joachim von Pawel, Ke Zhang, Paulina Selaru, Lesley Tye, Richard C. Chao, and Ramaswamy Govindan"]},"title":[{"subtitle":"a phase III trial","title_sort":"Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer","title":"Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer"}],"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"May 7, 2012"}],"person":[{"family":"Scagliotti","role":"aut","display":"Scagliotti, Giorgio V.","given":"Giorgio V."},{"given":"Michael","family":"Thomas","display":"Thomas, Michael","role":"aut"}],"id":{"doi":["10.1200/JCO.2011.39.2993"],"eki":["1581152930"]},"note":["Published online ahead of print on May 7, 2012","Gesehen am 20.09.2018"],"language":["eng"],"relHost":[{"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"physDesc":[{"extent":"Online-Ressource"}],"recId":"313116962","type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"pubHistory":["1.1983 -"],"language":["eng"],"disp":"Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer a phase III trialJournal of clinical oncology","title":[{"subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology"}],"origin":[{"dateIssuedDisp":"1983-","dateIssuedKey":"1983","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins"}],"id":{"zdb":["2005181-5"],"issn":["1527-7755"],"eki":["313116962"]},"part":{"issue":"17","volume":"30","extent":"9","text":"30(2012), 17, Seite 2070-2078","year":"2012","pages":"2070-2078"}}],"recId":"1581152930","physDesc":[{"extent":"9 S."}]} | ||
| SRT | |a SCAGLIOTTISUNITINIBP7201 | ||